GSK weighs 'staggered payments' for gene therapy Strimvelis

Quick on the heels of backing from a key European committee, GlaxoSmithKline ($GSK) is gearing up to launch Strimvelis, a breakthrough gene therapy for children. To lay that groundwork, the drugmaker is opening the door to radical changes in payments for the ultrapricey med to keep its cost from breaking the bank. More from FiercePharma

Suggested Articles

BMS' Opdivo and Yervoy only just won their first approval in previously untreated metastatic NSCLC, but the pair is already making it two.

Takeda’s Alunbrig has arrived in previously untreated, ALK-positive NSCLC. But there’s plenty of competition waiting to greet it at the door.

Sanofi and Regeneron's blockbuster Dupixent is eyeing an approval in eosinophilic esophagitis after cutting patients' difficulty breathing.